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ABSTRACT
Two hundred patients received hematopoietic stem cell transplantation (HSCT) from matched sibling donors
(MSD) after myeloablative conditioning including fludarabine (Flu) and once-daily intravenous busulfan (Bu).
Thymoglobulin (TG) was added to methotexate (MTX) and cyclosporine (CsA) as graft-versus-host disease
(GVHD) prophylaxis. For low-risk (acute leukemia CR1/CR2, CML CP1) patients projected 5-year nonrelapse
mortality (NRM) and overall survival (OS)were 4%and 76% for those#45 years old (n5 54) and 6%and 83% for
those.45 (n5 31). For high-risk (HR) patients NRMwas 6% versus 27% (18% at 1 year) (P5 .04) and OS 64%
versus 37% (P 5 .47) in younger (n 5 40) and older (n 5 75) patients, respectively. To correct for imbalance in
HR diagnoses each of 17 younger HR patients were matched with 2 older HR (OHR) patients by diagnosis and
details of stage, and thereafter for other risk factors. For the youngerHRandOHRpatients, respectively,OSwas
70% versus 37% (P 5 .02) and NRM 0 versus 34% (P 5 .02). When outcomes of OHR patients were compared
with the other 3 groups combined NRM was 27% versus 5%, respectively (P 5 .002). Incidence of acute graft-
versus-host disease (aGVHD) grade II-IV, aGVHD grade III-IV, and chronic GVHD (cGVHD) was 23% versus
10% (P5 .02), 4% versus 2% (P5ns), and 66% versus 41% (P5 .001), respectively. Nine of 14 nonrelapse deaths
in the OHR group were related to GVHD or its treatment compared with 3 of 6 in all others (P value for GVHD
related death 5 .01). Multivariate analysis of OS and DFS correcting for potentially confounding pretransplant
factors identified only theOHRpatients as having significantly increased risk (relative risk [RR] 3.32, confidence
interval [CI] 1.71-6.47, P\ .0001, and RR 3.32, CI 1.71-6.43, P\ .0001, respectively). The effect of age onNRM
is only apparent in HR patients, and is not explained by heterogeneity in diagnoses. Older HR patients experi-
ence more GVHD and more GVHD-related death than others, but NRM is no higher than reported with many
nonmyeloablative regimens.
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In recent years an intravenous (i.v.) formulation of
busulfan (Bu) has been replacing the oral drug in pre-
parative regimens for hematopoietic stem cell trans-
plantation (HSCT) [1-10]. Intravenous Bu has888demonstrably better bioavailability, less interpatient
variation in exposure, and lower toxicity than oral Bu
[1-10]. Combinations of Bu with fludarabine (Flu)
instead of cyclophosphamide (Cy) may result in effec-
tive and well-tolerated myeloablative conditioning
Risk Factors for NRM with Flu/Bu/Thymogobulin 889regimens [6,8]. Because the predominant cause of
morbidity and mortality after allogeneic HSCT re-
mains graft-versus-host disease (GVHD), we have
chosen to increase the GVHD prophylaxis for all pa-
tients rather than reduce the intensity of the condition-
ing for those considered to be at high risk of
nonrelapse mortality (NRM). There has been some
progress in prevention of GVHD using polyclonal an-
tibodies in the form of rabbit antithymocyte globulin
(ATG; Thymoglobulin, TG) [11-14]. Since 1999, all
allogeneic HSCT in our center have been performed
with a protocol based on Flu and once-daily i.v. Bu
(FLUBUP) with TG included in the GVHD prophy-
laxis [8,14,15]. Preliminary data indicated that the
combination was well tolerated by a group of patients
with hematologic malignancy transplanted from both
matched siblings (MSD) and alternative donors [8].
In the current analysis we report outcomes of HSCT
from MSD with particular respect to the influences
of age and disease risk.PATIENTS AND METHODS
Patients
The study includes 200 consecutive adults treated
with a first myeloablative HSCT between May 1999
and May 2005. Diagnoses and other details of the 2
groups are recorded in Table 1. Patients in second
complete remission (CR) are included in the low-risk
(LR) group as outcomes including NRM are similar
to those for CR1 patients with this regimen. The age
range was 18 to 65 years, with a median of 46 years.
This was primarily a study of NRM, which in these
patients was mainly influenced by disease risk. Analysis
of NRM in high-risk (HR) patients by 5-year age inter-
vals identified 45 years as the point at which NRM be-
gan to rise substantially. Patients were therefore
divided into 4 groups according to age #45 years or
.45 years and disease risk—LR or HR. Hematopoetic
stem cells (HSC) were collected from granulocyte-
colony stimulating factor mobilized blood for 172Table 1. Diagnoses and HSCT Characteristics of Each Group
Low-Risk #45 Years Low-Risk .45 Years High-Risk #45 Years High-Risk .45 Years
Number 54 31 40 75
Patient age (years) median (range) 37 (18-45) 50 (46-56) 40 (20-45) 54 (46-65)
Low-risk
AML CR1 27 (50%) 17 (55%)
AML CR2 3 (6%) 1 (3%)
ALL CR1 10 (19%) 3 (10%)
ALL CR2 2 (4%)
CML CP1 12 (22%) 10 (32%)
High-risk
AML advanced 6 (15%) 16 (21%)
ALL advanced 2 (5%) 3 (4%)
CML AP/CP2 5 (13%)* 1 (1%)*
CLL/SLL 4 (10%) 9 (12%)
NHL-follicular 5 (13%) 8 (11%)
NHL-other 5 (13%) 10 (13%)
MM 6 (15%) 7 (9%)
HD 5 (13%) 3 (4%)
MDS 1 (3%)† 14 (19%)†
MF 1 (1%)
PL 1 (1%)
HCL 1 (1%)
EO 1 (3%)
WM 1 (1%)
CMV 1 ve recipient and/or donor 38 (70%) 27 (87%) 30 (75%) 59 (79%)
Female to male HSCT 13 (24%) 7 (23%) 8 (20%) 25 (33%)
TBI 22 (41%) 9 (29%) 5 (13%) 10 (13%)
Blood as HSC source 42 (78%) 21 (68%) 39 (98%) 73 (97%)
CD 341 cell dose 106/kg median (range) 4.87 (0.75-11.20) 3.81 (1.47-13.52) 5.13 (1.84-11.57) 4.61 (0.83-13.57)
Statistical differences only reported within risk groups, for example, older versus younger HR patients.
AML indicates acute myelogenous leukemia/granulocytic sarcoma; CR, complete remission; ALL, acute lymphoblastic/biphenotypic leukemia;
CML, chronic myelogenous leukemia; CP, chronic phase; AP, accelerated phase; CLL, chronic lymphocytic leukemia/small lymphocytic
lymphoma6Richter’s transformation; NHL, non-Hodgkin lymphoma;MM,multiplemyeloma;HD,Hodgkin disease6CLL;MDS,mye-
lodysplasia; MF, myelofibrosis; PL, prolymphocytic leukemia; HCL, hairy cell leukemia; EO, eosinophilic leukemia; WM, Waldenstrom’s
macroglobulinemia; TBI, total body irradiation.
*P 5 .01.
†P 5 .02.
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marrow was largely used in patients with CML in
CP1, as our previous experience indicated that such
patients were particularly vulnerable to chronic
GVHD (cGVHD), which occurs more often after
blood cell transplants (BCT). Follow-up of survivors
was 13 to 87 months (median 42).
Treatment
The preparative chemotherapy comprised Flu 50
mg/m2 on days 26 to 22 and i.v. Bu (Busulfex, PDL
Pharma, Redwood City, CA) 3.2 mg/kg daily days
25 to 22 inclusive. Forty-six acute leukemia patients
had additional total body irradiation (TBI) 200 cGy
 2 on day 21 or 0. Busulfan pharmacokinetics were
followed in some patients but results were not used
to make dose adjustments.
Supportive care was similar for all patients. No
protective isolation was used [16]. Single-donor plate-
lets were given to maintain counts .10  109/L and
red cells to keep hemoglobin levels .80 g/L. Growth
factors were not given routinely. All patients received
twice weekly trimethoprim/sulfamethoxazole as pro-
phylaxis for Pneumocystis carinii. Antibacterial prophy-
laxis was ciprofloxacin 500 mg twice a day until 2003,
after which time no antibacterial antibiotics were given
routinely. Blood products were all from cytomegalovi-
rus (CMV) seronegative donors. A policy of surveil-
lance for pp65 antigen and pre-emptive therapy with
ganciclovir was used when donor and/or recipient
were CMV antibody positive. Routine monitoring
for Epstein-Barr virus (EBV) viral load was not done.
The acute GVHD (aGVHD) prophylaxis protocol in-
cluded cyclosporin A (CSA) orally or i.v. twice daily to
maintain blood levels between 150 and 400 mmol/L.
Methotrexate (MTX) was given at 15 mg/m2 intrave-
nously on day 1 and 10 mg/m2 on days 3, 6, and 11.
Folinic acid 5 mg intravenously or orally was started
24 hours after each MTX dose and continued every 6
hours until 12 hours before the next dose [17]. In addi-
tion, all patients were given rabbit ATG (TG ; Gen-
zyme, Cambridge, MA) 4.5 mg/kg i.v. in divided
doses over 3 days. Each dose was given as a continuous
infusion over 4 to 8 hours. To minimize reactions the
first dose was reduced to 0.5 mg/kg, the next 2 doses
were 2 mg/kg, the final infusion being given on the
day of transplant. Premedication included methypred-
nisolone 40 mg i.v. every 12 hours for 6 doses and be-
nadryl 50 mg i.v. before each dose of ATG.
If no aGVHD occurred CSA was tapered over 4 to
8 weeks with the intent to discontinue by 2 to 4
months.
Engraftment
Daily blood counts were done until discharge with
bone marrow aspirations at 3 months for survivingpatients and thereafter as clinically indicated. Granu-
locyte engraftment was defined as a count of .0.5 
109/L. The platelet count needed to be above 20 
109/L without transfusion for 3 days.
GVHD
aGVHDwas graded according to standard criteria
[18]. Grading was performed by physicians at onset
and during treatment with later confirmation and re-
cording by data managers.
aGVHD was treated with prednisone or methyl-
prednisolone initially while continuing CSA. First-
line therapy for steroid-resistant aGVHD was TG 2
mg/kg every other day for 2 to 4 doses while CSA
was withheld. cGVHD was treated with prednisone
with or without CSA with introduction of other agents
if response was incomplete.
Statistical Analysis
The Fisher’s exact test was applied to distribution
of numeric differences between groups and the 2-tailed
t-test test for comparison of means.
The distributions of time to events were compared
using the log rank test, with patients being censored
for relapse for estimation of NRM. For time to onset
of cGVHD, patients were censored at the time of
death, donor lymphocyte infusion (DLI), or second
transplant. Analysis was performed with GraphPad
Prism (GraphPad Corp., San Diego, CA).
The initial analysis assessed outcomes in the 4 sep-
arate groups. For a more robust univariate analysis of
GVHD and NRM the older HR (OHR) patients
were compared with the other 3 groups combined.
The analysis of risk factors associated with out-
comes was carried out by multivariate logistic regres-
sion models. Factors considered included age, sex,
disease risk, CMV antibody status, TBI, female-to-
male (F-M) HSCT, cell source, and CD341 cell
dose. The association of risk factors with overall sur-
vival (OS), disease-free survival (DFS), NRM, and re-
lapse was evaluated by using separate Cox proportion
hazard regression models. For nonrelapse death, re-
lapse was the competing risk event and, for relapse,
nonrelapse death was the competing risk event. All
multivariate analyses were done with SAS version
9.1. Relative risk (RR) for the 4 age/risk groups were
expressed relative to the young LR group.
For all analyses values for P of .05-.1 are referred to
as trends, and below .05 as significant.
Matched Pair Analysis
To establish whether differences in NRM between
older and younger HR patients could be explained by
heterogeneity in diagnosis a small matched pair analy-
sis was done. The database was searched for younger
patients who could be matched with 2 older ones. All
Risk Factors for NRM with Flu/Bu/Thymogobulin 891patients had to match for disease and disease status.
Acute leukemia patients were matched then for
cytogenetic risk. Thereafter, all cases were matched
if possible with controls for CMV status and female
to male HSCT. Seventeen younger patients were
matched with 34 older ones for this analysis. Details
are given in Table 2.
RESULTS
Engraftment
As engraftment and GVHD did not differ signifi-
cantly, data for bone marrow and BCT were com-
bined. One patient had graft failure, and 2 died
before day 28 without engraftment. The remaining
197 evaluable patients engrafted granulocytes at a
median of 16 days (range: 2-42). Platelets engrafted
in 195 patients at a median of 18 days (0-101). Patients
not engrafting include the 3 referred to above plus 2
who died before platelet engraftment on days 29
and 72.
GVHD
For the whole group, incidence of aGVHD grade
II-IV, aGVHD grade III-IV, and cGVHD was 14%
6 2%, 3%6 1%, and 54%6 4%, respectively. Com-
paring outcomes of OHR with the other 3 groups
combined gave figures of 23% versus 10% (P 5 .02),
4% versus 2% (P 5 ns), and 66% versus 41%, respec-
tively (P 5 .001) (Figure 1).
Bymultivariate logistic regression analysis the only
factors tending to influence aGVHD were male sex
(odds ratio [OR] 0.34 (0.11-1.04), P5 .06), F-M trans-
Table 2. Diagnoses and HSCT Characteristics of Each Group in
Matched-Pair Analysis
High-Risk
#45 Years
High-Risk
.45 Years
Number 17 34
Diagnosis
AML 1 2
AML (secondary, from MDS) NT 1 2
ALL 1 2
CLL 3 6
NHL-follicular 4 8
NHL-DLCL 1 2
NHL – MCL 1 2
MM 3 6
AML progressing from MDS NT 1 2
MDS (RA) 1 2
CMV 1 ve recipient and/or donor 12 (71%) 28 (82%)
Female-to-male SCT 2 (12%) 9 (26%)
TBI 1 (6%) 5 (15%)
Blood as stem cell source 17 (100%) 34 (100%)
CD 341 cell
dose 106/kg median (range)
4.9 (1.8-10.0) 4.4 (2.4-13.3)
NT indicates not treated; DLCL, diffuse large cell lymphoma;
MCL, mantle cell lymphoma; RA, refractory anemia; RAEB,
refractory anemia with excess blasts.plant (OR 3.09 [0.97-9.87], P 5 .06), and OHR status
(OR 1.90 [0.97-10.97], P5 0.05). There were trends to
influences on cGHVD by cell source (OR for BCT
2.62 [0.87-7.86], P 5 .09) and F-M transplant (OR
2.12 [0.99-4.42], P 5 0.05).
NRM
Table 3 gives the causes of nonrelapse death in the
older HR patients and the other 3 groups combined.
Nine of 14 nonrelapse deaths in the OHR group
were related to GVHD or its treatment compared
with 3 of 6 in all others (P value for GVHD related
death 5 .01). Of the total of 12 GVHD related deaths
2 were from aGVHD. All 10 deaths related to cGVHD
occurred in patients with progressive cGVHD, that is,
cGVHD developing during treatment of aGVHD.
Thus, no patient died from cGVHD with onset after
the initial CSA taper.
For LR patients 3 year NRM was 4% 6 3% for
those#45 years old and 6%6 4% for those.45 (Ta-
ble 4). Corresponding figures forHR patients were 6%
6 4% and 27%6 7% (18%6 5% at 1 year) (P5 .04).
Comparing NRM of OHR patients with the other 3
groups combined gave figures of 27% versus 5%, re-
spectively (P 5 .002) (Figure 2). Above the age of 45
years there was no further trend to increase in NRM.
Thus, for 46 patients younger than 55 years, NRM
was 29% compared with 20% in 29 patients aged
$55 years (P 5 ns). The difference in NRM between
OHR and older LR patients is therefore not because
of the lower proportion of patients (3 of 45) aged be-
tween 55 and 65 years in the former group.
0 25 50 75 100
0
10
20
30
days
II-IV 3 groups combined
III-IV 3 groups combined
II-IV OHR
III-IV OHR
%
 
a
c
u
t
e
G
V
H
D
0 100 200 300 400 500 600
0
25
50
75
100
days
3 groups combined
OHR
%
 
c
G
V
H
D
A
B
Figure 1. Kaplan-Meier plots of GVHD. (A) aGVHD; (B) cGVHD
in OHR and the other 3 groups combined.
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Death before Day 100 Death after Day 100* Total Deaths
High-risk . 45 (n 5 75) Myocardial infarct (1)
Candidiasis (1)
Influenza B (1)
Acute GVHD (1)
GVHD related (8) – (2 aspergillus)
Pulmonary embolus (1)
Graft failure (1)
14
Other 3 groups
combined (n 5 125)
Veno-occlusive disease (1) GVHD related (3) – (1 varicella)
Adult respiratory distress syndrome (1)
Pneumonia (1)
6
*Includes identified opportunistic infection when death was GVHD related.By multivariate analysis the only pretransplant fac-
tor leading to higher NRM was the combination of
HR and older patient age (RR 6.95 [95% CI 1.54-
31.32], P 5 .01). aGVHD was a significant risk factor
for NRM (RR 9.0 [2.98-27.19], P\ .001).
Relapse
Relapse frequency was significantly higher in the
OHR patients (RR 3.24 [1.53-6.90], P 5 .002). There
was a trend to less relapse in patients living beyond 3
months who developed cGVHD (RR 0.57 [0.3-1.07],
P 5 .08).
DFS and OS
Table 4 gives figures for OS and DFS of the 4
groups. Bymultivariate analysis OHR patients had sig-
nificantly lower OS (RR 3.32 [1.71-6.47], P\ .001)
and DFS (RR 3.32 [1.71-6.43], P\ .001).
OS was worse if aGVHD occurred (RR 1.95 [1.02-
3.72], P 5 .04). In patients surviving .3 months OS
and DFS were better in those developing cGVHD
(RR 0.5 [0.28-0.89], P 5 .02 for OS, RR 0.45
[0.25-0.81], P5 .008 for DFS). There was also a trend
to better DFS (RR 0.55 [0.29-1.06], P5 .07) with F-M
HSCT.
Matched-Pair Analysis
For the 17 younger HR and 34 OHR patients, re-
spectively, OS was 70% versus 37% (P 5 .02), NRM
0% versus 34% (P 5 .02), and relapse 48% versus
46% at 3 years (P 5 ns). Incidence of aGVHD grade
II-IV, aGVHD grade III-IV, and cGVHD was 6%
versus 28% (P 5 .06), 0% versus 3% (P 5 ns), and
57% versus 70% (P 5 ns), respectively. Seven of the
Table 4. Outcomes at 3 Years by Age and Risk
Low-Risk
#45 Years
Low-Risk
.45 Years
High-Risk
#45 Years
High-Risk
.45 Years
Number 54 31 40 75
OS 76% ± 6% 83% ± 7% 64% ± 8% 37% ± 7%
DFS 72% ± 6% 74% ± 8% 43% ± 9% 34% ± 6%
NRM 4% ± 3% 6% ± 4% 6% ± 4%* 27% ± 7%*
Relapse 25% ± 6% 21% ± 8% 51% ± 8% 52% ± 6%
*P 5 .04.9 deaths in the OHR group were GVHD related (P
value for GHVD related death 5 .08).
DISCUSSION
Oral Bu with Cy (BuCy) became established for
many years as a standard conditioning regimen for allo-
geneic HSCT [19,20]. This combination had the ad-
vantage that facilities for TBI were not necessary.
Regimen-related toxicity, however, was still substan-
tial, particularly that of veno-occlusive disease (VOD)
[21,22]. The original intent of our FLUBUP protocol
was to improve tolerability by replacing Cy in BuCy
withFlu. Flu has other attributes; it is effective in leuke-
mias and lymphomas, is a powerful immunosuppres-
sant, and theoretically might have a synergistic effect
in combination with Bu [23]. Our initial experience
with oral Bu and Flu indicated a similar toxicity profile
to BuCy [24].When i.v. Bu became available, we inves-
tigated the possibility of once daily administration. In
combination with Flu, the toxic effects were similar to
those of oral Bu apart from a modestly reduced inci-
dence of stomatitis [25]. Little VOD was seen in either
group.Other reports have indicated that i.v. Bu is better
tolerated than the oral formwith less inter- and intrapa-
tient variability in exposure [1-10].
Although the toxicity of the preparative regimen
contributes to NRM, GVHD usually remains the
0 12 24 36 48 60 72 84 96
0
25
50
75
100
months
3 groups combined
OHR
%
 
T
R
M
Figure 2. Kaplan-Meier plots of NRM in OHR and the other 3
groups combined.
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blood as a source of HSC has resulted in more
cGVHD [26]. When TG was added to an MTX/CSA
regimen for recipients of bone marrow transplants
from unrelated donors, outcomes were very similar
to those achieved by MSD HSCT [13]. It therefore
seemed rational to add TG to the regimen for MSD
HSCT. Since 1999 we have used FLUBUP-based
conditioning withTG included in theGVHDprophy-
laxis for all allogeneic transplants. In LR patients and
younger ones with HR disease, this regimen results
in a low incidence of aGVHD and NRM. Older pa-
tients with HR disease have significantly more
GVHD and higher NRM than the others. Although
this is not surprising, it is noteworthy that higher age
was not associated with more NRM in LR patients.
The HR patients had a variety of hematologic malig-
nancies, and it was possible that the effect of age on
NRM might reflect different proportions of patients
with particular diagnoses in the 2 groups. Thus, for ex-
ample, the older group hadmore individuals withmye-
lodysplastic syndrome (MDS) and fewer with HD and
chronic myelogenous leukemia (CML) than the youn-
ger group. To correct for this imbalance we did a small
matched pair analysis, demonstrating that the differ-
ence inNRMwas not because of differences in diagno-
sis. Although the numbers in this analysis are too small
to detect more than trends, the treatment-related
deaths were mostly from GVHD. There appears to
be little or no compensatory decrease in relapse so
DFS is significantly affected.
TGmay reduce the incidence of both aGVHDand
cGVHD, thereby contributing to lower NRM
[11,12,14]. Although the incidence of cGVHD in
this study is substantial, it is lower than our historic ex-
perience of patients treated without TG [14]. In the
current study, aGVHD was associated with higher
NRM and worse OS and DFS, whereas cGVHD
reduced relapse and improved final outcomes. Death
associated with GVHD was largely related to progres-
sive cGVHD and contributed significantly to the
higher NRM seen in the OHR patients. Attempts to
reduce NRM should therefore be directed primarily
to this group. The challenge is to prevent lethal
GVHD; however, the risk of simply escalating im-
mune suppression would be that of abrogating the
graft-versus-myeloma (GVM) effect.
There is evidence that the tolerability of the reg-
imen could be improved by monitoring Bu pharma-
cokinetics. Toxic effects of oral Bu given with Cy
increase with high Bu exposures [27-30]. This is
also the case for i.v. Bu when given with Flu; in
fact, the threshold at which a significant effect on
NRM occurs is very similar to that previously ob-
served with BuCy [27,31]. Although high exposure
could at least partly be a surrogate marker for im-
paired ability to metabolize many agents [32], it is ra-tional to avoid overexposure either by test dosing
and/or by monitoring during treatment with subse-
quent dose adjustment [33].
The main cause of treatment failure in all groups
remains that of persistent or relapsing disease. Some
diseases, acute myelogenous leukemia (AML), for ex-
ample, may benefit from higher dose intensity of the
conditioning. Studies of this approach with other reg-
imens have sometimes resulted in higher NRMwith or
without reducing relapse [34,35]. There is evidence
that adding 2 fractions of 200 cGy TBI to FLUBUP
does not increase NRM, but can reduce relapse in
AML [36]. The ability to monitor Bu pharmacokinet-
ics also allows Bu exposures to be targeted to a point
relatively high in the therapeutic range either by dose
adjustment during therapy or by using a test dose
[33]. Other conditions may be less amenable to dose
intensification of the cytoreductive agents. In these
cases enhancing the GVM effect, for example by
DLI, might be more appropriate.
Using a single regimen for all patients has the
advantage of convenience. The OHR patients might
otherwise be considered as candidates for nonmyeloa-
blative or ‘‘reduced-intensity’’ HSCT regimens [37-39].
Such protocols are now widely used for older patients
and those with comorbidities. There is some evidence
that relapse is higher than with myeloablative regi-
mens, whereas NRM is comparable to that seen in
our OHR patients [37-39]. Our approach has been to
maintain the dose intensity of the conditioning, while
enhancing the GVHD prophylaxis. The result appears
to be a regimen of comparable intensity to traditional
myeloablative protocols without the accompanying
NRM.
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